PharmaEngine, Inc. Receives Approval of US IND Application for a Phase II Study of PEP02 (Liposome Irinotecan Injection) in Pancreatic Cancer
12/3/2008 9:21:16 AM
TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. announced today that it has received approval of an Investigational New Drug (IND) application from the U.S. FDA for PEP02, a liposome formulation of irinotecan in a phase II study in patients with metastatic pancreatic cancer. Previous phase I data showed excellent pharmacokinetics, tolerability and efficacy of PEP02 in advanced solid tumor patients in a poster presented at 2008 ASCO Annual Meeting.
comments powered by